The Molecular Subtype Classification Is a Determinant of Sentinel Node Positivity in Early Breast Carcinoma

Introduction Several authors have underscored a strong relation between the molecular subtypes and the axillary status of breast cancer patients. The aim of our work was to decipher the interaction between this classification and the probability of a positive sentinel node biopsy. Materials and Methods Our dataset consisted of a total number of 2654 early-stage breast cancer patients. Patients treated at first by conservative breast surgery plus sentinel node biopsies were selected. A multivariate logistic regression model was trained and validated. Interaction covariate between ER and HER2 markers was a forced input of this model. The performance of the multivariate model in the training and the two validation sets was analyzed in terms of discrimination and calibration. Probability of axillary metastasis was detailed for each molecular subtype. Results The interaction covariate between ER and HER2 status was a stronger predictor (p = 0.0031) of positive sentinel node biopsy than the ER status by itself (p = 0.016). A multivariate model to determine the probability of sentinel node positivity was defined with the following variables; tumour size, lympho-vascular invasion, molecular subtypes and age at diagnosis. This model showed similar results in terms of discrimination (AUC = 0.72/0.73/0.72) and calibration (HL p = 0.28/0.05/0.11) in the training and validation sets. The interaction between molecular subtypes, tumour size and sentinel nodes status was approximated. Discussion We showed that biologically-driven analyses are able to build new models with higher performance in terms of breast cancer axillary status prediction. The molecular subtype classification strongly interacts with the axillary and distant metastasis process.

[1]  P. V. van Diest,et al.  Prognostic value of proliferative activity in lymph node metastases of patients with breast cancer. , 1991, Journal of clinical pathology.

[2]  Sung-Bae Kim,et al.  Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. , 2006, Human pathology.

[3]  D. Promish Prediction of axillary lymph node involvement of women with invasive breast carcinoma , 1999 .

[4]  S. Huffel,et al.  Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive , 2008, Breast Cancer Research and Treatment.

[5]  J. Peterse,et al.  Reproducibility of mitosis counting in 2,469 breast cancer specimens: results from the Multicenter Morphometric Mammary Carcinoma Project. , 1992, Human pathology.

[6]  E. Petru,et al.  T1 Breast Cancer: Identification of Patients at Low Risk of Axillary Lymph Node Metastases , 2002, Breast Cancer Research and Treatment.

[7]  T. Megha,et al.  Prediction of lymph node status by analysis of prognostic factors and possible indications for elective axillary dissection in T1 breast cancers. , 2001, The European journal of surgery = Acta chirurgica.

[8]  C. Perou,et al.  Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. , 2005, Cancer research.

[9]  Xuesong Lu,et al.  Predicting features of breast cancer with gene expression patterns , 2008, Breast Cancer Research and Treatment.

[10]  T. Nielsen,et al.  Breast cancer subtypes and the risk of local and regional relapse. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  P. V. van Diest,et al.  Data processing and analysis in the Multicenter Morphometric Mammary Carcinoma Project (MMMCP). , 1989, Pathology, research and practice.

[12]  J. Mackey,et al.  Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  S. Leung,et al.  Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer. , 2008, Clinical breast cancer.

[14]  F. Meng,et al.  Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers. , 2008, Human pathology.

[15]  Y. Suh,et al.  Predictors of axillary lymph node metastases (ALNM) in a Korean population with T1-2 breast carcinoma: triple negative breast cancer has a high incidence of ALNM irrespective of the tumor size. , 2010, Cancer research and treatment : official journal of Korean Cancer Association.

[16]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[17]  Roman Rouzier,et al.  Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy , 2005, Clinical Cancer Research.

[18]  P M Ravdin,et al.  Prediction of axillary lymph node status in breast cancer patients by use of prognostic indicators. , 1994, Journal of the National Cancer Institute.

[19]  Tanja Fehm,et al.  Prediction of Axillary Lymph Node Status of Breast Cancer Patients by Tumorbiological Factors of the Primary Tumor , 2005, Strahlentherapie und Onkologie.

[20]  C. Yip,et al.  Predictors of Axillary Lymph Node Metastases in Breast Cancer: Is There a Role for Minimal Axillary Surgery? , 2008, World Journal of Surgery.

[21]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[22]  A. Ashworth,et al.  Breast cancer molecular profiling with single sample predictors: a retrospective analysis. , 2010, The Lancet. Oncology.

[23]  J. Val-Bernal,et al.  Predictors of axillary lymph node metastases in patients with invasive breast carcinoma by a combination of classical and biological prognostic factors. , 1999, Pathology, research and practice.

[24]  R. Dahiya,et al.  Wnt Antagonist Gene DKK2 Is Epigenetically Silenced and Inhibits Renal Cancer Progression through Apoptotic and Cell Cycle Pathways , 2009, Clinical Cancer Research.

[25]  A. Vincent-Salomon,et al.  Histological Detection of Minimal Metastatic Involvement in Axillary Sentinel Nodes: A Rational Basis for a Sensitive Methodology Usable in Daily Practice , 2002, Modern Pathology.

[26]  M. Silverstein,et al.  Predictors of axillary lymph node metastases in patients with T1 breast carcinoma. , 1997, Cancer.

[27]  R. Simmons,et al.  Predictive factors associated with axillary lymph node metastases in T1a and T1b breast carcinomas: analysis in more than 900 patients. , 2000, Journal of the American College of Surgeons.

[28]  Barbara L. Smith,et al.  Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Carlos Caldas,et al.  A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the Proliferation, Immune response and RNA splicing modules in breast cancer , 2008, Breast Cancer Research.

[30]  C. Sotiriou,et al.  Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures , 2007, Breast Cancer Research.

[31]  John W M Martens,et al.  Subtypes of breast cancer show preferential site of relapse. , 2008, Cancer research.